By virtue of Department Order No. 393-E series of 2000, the Research Institute for Tropical Medicine was designated as the National Reference Laboratory for confirmatory testing of blood donors and units. Under Memorandum Circular No. 126, the Transfusion Transmissible Infections – National Reference Laboratory (TTI-NRL) is mandated to perform confirmatory testing of blood donors and units screened reactive for Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus 1&2, Syphilis and Malaria among blood banks and blood service facilities nationwide. It also provides quality assurance and identify areas for improvement on:
a. Technical Procedures (specificity validation and monitoring of accuracy; site visits)
b. Kit Performance (evaluation through monitoring of screening test results)
c. Provide an External Quality Assessment Scheme to Blood Service Facilities
TTI-NRL provides recommendations and strategies to ensure the safety of blood supply from transfusion transmissible infections and quality assurance as a whole. It trains Medical Technologists of blood banks and/or blood service facilities on testing transfusion transmissible infections and conducts researches to provide data and improve the quality of testing among blood service facilities.
To be the center of excellence in performing quality procedures, trainings, and researches for the elimination of risks associated with transfusion transmissible infections.
The TTI-NRL ensures the safety of the national blood supply through confirmation of reactive blood units, provision of quality assurance and technical trainings, evaluation of test kit performance and the conduct of researches for the standardization of blood screening of Blood Service Facilities in the Philippines.
- CONFIRMATORY TESTING
The TTI-NRL delivers a range of testing services for reference testing of screened reactive blood donors to HIV, Hepatitis B and C, Syphilis and Malaria and these services are offered to all blood screening facilities nationwide. Our testing services involve serological and molecular tests to give the most satisfactory and accurate diagnoses.
- Confirmatory Request Form (PDF | XLS)
- Referral Guidelines
- Dried Blood Spot Preparation
- Hepatitis B Cut-Off Points (DC2012-0198)
- NCBS – Technical Committee Recommendations, Strategies, Methodologies and Algorithms for Testing Blood Units for Transfusion Transmissible Infection (DC2013-0132)
- Amendment to DC2013-0132 (Sensitivity and Specificity)
- Quarterly Report Forms (Hepatitis B Cut-Off | TTI Report)
We provide a range of training services as an approach to build and enhance quality in laboratory systems for blood service facilities. Our training programs are designed to promote self-sufficiency and sustainability that will aid in the development of technical and analytical skills of the participant and also to promote best practices in laboratory testing. We deliver specialized training in HIV and other TTI Proficiency Testing and Biosafety Practices for medical technologists in blood service facilities.
Due to the RITM response with the COVID-19 pandemic, we have cancelled all face-to-face events including trainings. Enrollments for all remaining 2020 courses are currently suspended until further notice with the exception on the online refresher course scheduled 27 October.
2021 HIV and other TTI Proficiency Testing Training Workshop Schedule:
26 April to 01 May
14 June to 19 June
c. 09 August to 14 August
d. 11 October to 16 October
Refresher Course –
05 AprilThe workshop will be conducted online and for more information on the details and registration, please visit the RITM Learning and Development System.
- QUALITY ASSURANCE
To achieve the highest level of accuracy and reliability, it is essential that best practices are observed in the laboratory through the following activities:
External Quality Assessment Scheme (EQAS)
The TTI Serology EQAS generates valuable information on the types and brands of assays used in the country. This can provide a better overview of blood service facilities carrying out serological tests of transfusion transmissible infections as well as their activities. With this, we can monitor the performance of laboratories and identify those which require training to improve their performance. Participating laboratory can learn from the results and can be reassured that their performance is up to standard or they will be made aware to correct problems that would otherwise have gone unnoticed. Strategies and recommendation are provided to strengthen the performance of each participating laboratory.
The 2020 test event cycle for Transfusion Transmissible Infections was suspended along with the other programs offered by the Research Institute for Tropical Medicine due to the on-going response to the COVID-19 pandemic (please read DOH issuance 2020-0306).
Relative to the licensing requirements, the 2021 test event cycle will resume and is scheduled as follows:
Test Event 1
ANNOUNCEMENT: Shipment date has been put ON HOLD and updates will be made available as soon as possible. Participants are advised to keep their emails open and up to date
Test Event Deadline:
Test Event 2
Shipment Date: 22 September
Test Event Deadline: 29 September
We are reopening the registration for the TTI EQAS program in consideration for the participants who were not able to comply with the 30 September 2020 deadline. Registration will be accepted on or before 31 March 2021.
For more information on the registration, please send us an email at firstname.lastname@example.org.
With the EQAS results, monitoring of blood banks/blood service facilities are made to assess the quality, accuracy and reliability of laboratory testing results and the extent and nature of laboratory-related problems and errors. This covers every step in the procedure, from sample receipt through the final interpretation of the donor result.
Provision of Quality Control Samples
To assure that test runs are valid and reliable, external quality control samples should be used in the performance of each assay. These samples should be treated the same way as donor samples and are used to validate the test run.
The interest of the TTI-NRL to perform researches as one of its mandates led the way in forming the Transfusion Transmissible Infections Study Group comprised of different infectious disease specialists of the Research Institute for Tropical Medicine.
Department of Health Issuances
- Implementing Guidelines and Standard Procedures for the National Blood Bank Network System (NBBNetS)
(Department Order 2013-0073 | 14 June 2013)
- Reiteration of the New Maximum Allowable Service Fees for Whole Blood and Blood Components in Blood Service Facilities
(Department Circular No. 2016-0318 | 09 November 2016)
- Guidelines on the Issuance of Certificate of Inclusion to Blood Services Network
(Department Memorandum 2016-0448 | 14 December 2016)
- Interim Guidelines on Reducing the Risk of Zika Virus Transmission Through Blood Transfusion
(Department Memorandum 2016-0453 | 14 December 2016)
- Designation of Lead Blood Service Facilities
(Department Memorandum 2016-0451 | 28 December 2016)
- Extension of Compliance to Certificate of Participation/Proficiency (COP) Conducted by National Reference Laboratories (NRLs) as a Regulatory Requirement for Licensing of Clinical Laboratories
(Department Memorandum 2017-0185 | 10 April 2017)
- Agreement on the New Timelines for the Application and Issuance of Certificate of Performance / Certificates of Proficiency of External Quality Assessment Program (EQAP) Conducted by National Reference Labroatories (NRLs)
(Department Circular No. 2017-0173 | 19 May 2017)
- Updated List of DOH-Designated HIV Treatment Hubs and Satellite Treatment Hubs
(Department Memorandum 2018-0031 | 18 January 2018)
- Participation of Clinical Laboratories and Blood Service Facilities in the External Quality Assessment Program which are not applicable for their category.
(Department Memorandum 2018-0062 | 12 February 2018)
- Reiteration of the No Re-testing Policy of Blood Units and the Set Maximum Allowable Service Fees for Whole Blood and Blood Components in Blood Service Facilities
(Department Circular No. 2018-0348 | 03 August 2018)
- Towards 100% Voluntary Blood Donation by 2020 for Blood Safety, Patient Safety and Quality Care
(Department Circular No. 2018-0324 | 03 August 2018)
- Provision of Blood and Blood Products to Patients of Health Facilities
(Department Circular No. 2018-0406 | 03 September 2018)
- Personnel Requirements for Blood Centers
(Department Circular No. 2018-0405 | 03 September 2018)
- Interim Guidelines on Transportation of Biological Specimens
(Department Memorandum 2018-0413 | 20 November 2018)
- Updated Guidelines for the Bi-Annual Proficiency Test for Transfusion Transmissible Infections (TTIs) Serology
(Department Circular No. 2019-0227 | 22 May 2019)
- Referral of Nonreactive Blood Unit samples for validation of Transfusion Transmissible Infections (TTIs) by Blood Service Facilities
(Department Circular No. 2019-0228 | 22 May 2019)
- Guidelines on the Initial Implementation of No Family/Replacement Blood Donation Policy in Selected DOH-Hospital Blood Banks
(Department Order No. 2020-0070 | 24 February 2020)
- Interim Guidelines on Ensuring Blood Safety and Adequacy for COVID-19 Response
(Department Memorandum No. 2020-0124 | 18 March 2020)
- Reiteration of National Voluntary Blood Services Program (NVBSP) Issuances Concerning No Paid Donation for Conventional Donation, Apheresis Donation, and Convalescent Plasma Donation
(Department Circular No. 2020-0312 | 08 August 2020)
- National Blood Services Act of 1994
(Republic Act 7719 | 05 May 1994)
- Philippine HIV and AIDS Policy Act
(Republic Act 11166 | 20 December 2018)
Manual of Standards
- Philippine Clinical Practice Guidelines for the Rational Use of Blood and Blood Products and Strategies for Implementation (2010)
- Manual of Standards for Blood Service Facilities (2011)
- Manual on Blood Donor Selection and Counseling (2011)
For inquiries, please contact us through the following:
Direct Line: +63 2 8808 2552
Trunkline: +63 2 8807 2628 local 229
Mobile: +63 998 459 5982 (Smart) | +63 916 639 3402 (Globe)